Publications by authors named "Kenneth Grossmann"

Claim this Profile
R
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Kenneth F Grossmann

Cancer Discov· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.
Ari VanderWalde, Shay L Bellasea, Kari L Kendra, Nikhil I Khushalani, Katie M Campbell, Kenneth F Grossmann

Nat Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma.
Elise K Brunsgaard, Tawnya L Bowles, Elliot A Asare, Kenneth Grossmann, Kenneth M Boucher, Allie Grossmann

Melanoma Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review.
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J Lee, Kenneth F Grossmann

Cancers (Basel)· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright, Kathleen J Yost, Kenneth F Grossmann

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Joseph M Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Kenneth Grossmann

JAMA Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Kenneth F Grossmann, Megan Othus, Sapna P Patel, Ahmad A Tarhini, Vernon K Sondak

Cancer Discov· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R McWilliams, Olivier Rixe, Joseph Drabick, Montaser F Shaheen, Kenneth F Grossmann

J Immunother Cancer· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dark side of immunotherapy.
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, Kenneth F Grossmann, Umang Swami

Ann Transl Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Kelsey Baron, Justin C Moser, Shiven Patel, Kenneth F Grossmann, Sarah V Colonna

J Oncol Pharm Pract· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
Susan M Swetter, John A Thompson, Mark R Albertini, Christopher A Barker, Joel Baumgartner, Kenneth Grossmann

J Natl Compr Canc Netw· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Rebecca Pokorny, Jordan P McPherson, Benjamin Haaland, Kenneth F Grossmann, Carolyn Luckett

J Immunother Cancer· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial.
Alain P Algazi, Megan Othus, Adil I Daud, Roger S Lo, Janice M Mehnert, Kenneth F Grossmann

Nat Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
Douglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, Michael A Marchetti, Megan Othus, Kenneth F Grossmann

JAMA Dermatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.
Amanda Truong, John R Hyngstrom, Robert H I Andtbacka, R Dirk Noyes, Melissa Wright, Kenneth F Grossmann

Melanoma Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
Justin C Moser, Guo Wei, Sarah V Colonna, Kenneth F Grossmann, Shiven Patel

Acta Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Justin C Moser, Danli Chen, Siwen Hu-Lieskovan, Kenneth F Grossmann, Shiven Patel

Cancer Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011).
Douglas Grossman, James M Farnham, John Hyngstrom, Marki E Klapperich, Aaron M Secrest, Kenneth Grossmann

J Am Acad Dermatol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, Jason C Chandler, Andrew Weickhardt, Kenneth F Grossmann

Br J Clin Pharmacol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin, David Minor, Sandra D'Angelo, Bart Neyns, Michael Smylie, Kenneth Grossmann

J Clin Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Dirk Schadendorf, Jedd D Wolchok, F Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Kenneth Grossmann

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Laura J Gardner, Morgan Ward, Robert H I Andtbacka, Kenneth M Boucher, Glen M Bowen, Kenneth Grossmann

Melanoma Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study.
Justin C Sowder, Richard B Cannon, Luke O Buchmann, Jason P Hunt, Ying Hitchcock, Kenneth F Grossmann

Head Neck· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.
Mariah M Johnson, Sancy A Leachman, Lisa G Aspinwall, Lee D Cranmer, Clara Curiel-Lewandrowski, Kenneth F Grossmann

Melanoma Manag· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Antonio Jimeno, Marshall R Posner, Lori J Wirth, Nabil F Saba, Roger B Cohen, Kenneth F Grossmann

Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis